627 related articles for article (PubMed ID: 28289035)
21. PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability.
Montaner M; Lopez-Argüello S; Oliver A; Moya B
Microbiol Spectr; 2023 Feb; 11(1):e0303822. PubMed ID: 36475840
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hope.
Avery LM; Mullane EM; Nicolau DP
Int J Antimicrob Agents; 2020 Feb; 55(2):105863. PubMed ID: 31870597
[TBL] [Abstract][Full Text] [Related]
23. In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.
Le Terrier C; Nordmann P; Poirel L
J Antimicrob Chemother; 2022 Dec; 78(1):101-107. PubMed ID: 36308322
[TBL] [Abstract][Full Text] [Related]
24. Transcending the challenge of evolving resistance mechanisms in
Hujer AM; Marshall SH; Mack AR; Hujer KM; Bakthavatchalam YD; Umarkar K; Palwe SR; Takalkar S; Joshi PR; Shrivastava R; Periasamy H; Bhagwat SS; Patel MV; Veeraraghavan B; Bonomo RA
mBio; 2023 Oct; 14(6):e0111823. PubMed ID: 37889005
[TBL] [Abstract][Full Text] [Related]
25. Activity of Meropenem with a Novel Broader-Spectrum β-Lactamase Inhibitor, WCK 4234, against Gram-Negative Pathogens Endemic to New York City.
Iregui A; Khan Z; Landman D; Quale J
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611363
[TBL] [Abstract][Full Text] [Related]
26. Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment.
Preston RA; Mamikonyan G; DeGraff S; Chiou J; Kemper CJ; Xu A; Mastim M; Yeole R; Chavan R; Patel A; Friedland HD; Bhatia A
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397067
[TBL] [Abstract][Full Text] [Related]
27. Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects.
Rodvold KA; Gotfried MH; Chugh R; Gupta M; Patel A; Chavan R; Yeole R; Friedland HD; Bhatia A
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784852
[TBL] [Abstract][Full Text] [Related]
28. New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship.
Jean SS; Gould IM; Lee WS; Hsueh PR;
Drugs; 2019 May; 79(7):705-714. PubMed ID: 30972660
[TBL] [Abstract][Full Text] [Related]
29. Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases.
Livermore DM; Mushtaq S; Warner M; Woodford N
J Antimicrob Chemother; 2015 Nov; 70(11):3032-41. PubMed ID: 26311835
[TBL] [Abstract][Full Text] [Related]
30. In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy.
Barceló I; Cabot G; Palwe S; Joshi P; Takalkar S; Periasamy H; Cortés-Lara S; Zamorano L; Sánchez-Diener I; Moya B; Bhagwat S; Patel M; Oliver A
J Antimicrob Chemother; 2021 Sep; 76(10):2546-2557. PubMed ID: 34219168
[TBL] [Abstract][Full Text] [Related]
31.
Monogue ML; Tabor-Rennie J; Abdelraouf K; Nicolau DP
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31235557
[TBL] [Abstract][Full Text] [Related]
32. Activity of β-lactam plus β-lactam-enhancer combination cefepime/zidebactam against Klebsiella pneumoniae harbouring defective OmpK35/36 porins and carbapenemases.
Joshi P; Shrivastava R; Bhagwat S; Patel M
Diagn Microbiol Infect Dis; 2021 Oct; 101(2):115481. PubMed ID: 34332307
[TBL] [Abstract][Full Text] [Related]
33. Role of Pseudomonas aeruginosa low-molecular-mass penicillin-binding proteins in AmpC expression, β-lactam resistance, and peptidoglycan structure.
Ropy A; Cabot G; Sánchez-Diener I; Aguilera C; Moya B; Ayala JA; Oliver A
Antimicrob Agents Chemother; 2015 Jul; 59(7):3925-34. PubMed ID: 25896695
[TBL] [Abstract][Full Text] [Related]
34. Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia.
Tirlangi PK; Wanve BS; Dubbudu RR; Yadav BS; Kumar LS; Gupta A; Sree RA; Challa HPR; Reddy PN
Antimicrob Agents Chemother; 2023 Jun; 67(8):e0050023. PubMed ID: 37314343
[TBL] [Abstract][Full Text] [Related]
35. In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.
Gethers M; Chen I; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2022 Jun; 77(7):1931-1937. PubMed ID: 35411395
[TBL] [Abstract][Full Text] [Related]
36. Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing
Vázquez-Ucha JC; Lasarte-Monterrubio C; Guijarro-Sánchez P; Oviaño M; Álvarez-Fraga L; Alonso-García I; Arca-Suárez J; Bou G; Beceiro A;
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0167621. PubMed ID: 34807754
[TBL] [Abstract][Full Text] [Related]
37. OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'.
Morinaka A; Tsutsumi Y; Yamada M; Suzuki K; Watanabe T; Abe T; Furuuchi T; Inamura S; Sakamaki Y; Mitsuhashi N; Ida T; Livermore DM
J Antimicrob Chemother; 2015 Oct; 70(10):2779-86. PubMed ID: 26089439
[TBL] [Abstract][Full Text] [Related]
38. New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the
Kaushik A; Ammerman NC; Parrish NM; Nuermberger EL
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31209013
[TBL] [Abstract][Full Text] [Related]
39. Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report.
Dubey D; Roy M; Shah TH; Bano N; Kulshrestha V; Mitra S; Sangwan P; Dubey M; Imran A; Jain B; Velmurugan A; Bakthavatchalam YD; Veeraraghavan B
Ann Clin Microbiol Antimicrob; 2023 Jul; 22(1):55. PubMed ID: 37408075
[TBL] [Abstract][Full Text] [Related]
40. New β-Lactam-β-Lactamase Inhibitor Combinations.
Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]